Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27955233 | 0.91 | ESR2 (0.38) | MRGPRX4ESR2STSSCN5ASCN9A | |
| SCHEMBL27996339 | 0.82 | ESR2 (0.53) | MRGPRX4ESR2STSKCNH2SLC6A2 | |
| SCHEMBL2161069 | 0.81 | HAO1 (0.44) | KCNH2NPC1RAB9APOLB | |
| SCHEMBL19107723 | 0.79 | PARP10 (0.41) | — | |
| SCHEMBL14451341 | 0.76 | CYP2C9 (0.55) | SPHK1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8598760 | 0.76 | KDM1A (0.55) | KDM1AMAOBSPHK1SLC6A2SLC6A4 | |
| SCHEMBL17729977 | 0.76 | KDM1A (0.55) | KDM1AMAOBSPHK1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL28414618 | 0.74 | KDM1A (0.56) | KDM1AMAOBSPHK1SLC6A2SLC6A4 | |
| SCHEMBL18511951 | 0.73 | THRB (0.43) | KDM1AMAOBSPHK1MRGPRX4ESR2 | |
| SCHEMBL7698322 | 0.73 | KDM1A (0.58) | KDM1AMAOBSPHK1SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080177036-A1 | Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity | CHEN LI | 2008-07-24 | — | — | US | disclosed |
| EP-1272516-B1 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| EP-1315750-B1 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2007-02-14 | — | — | EP | disclosed |
| US-7045591-B2 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050239711-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI | 2005-10-27 | — | — | US | disclosed |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2003-12-11 | — | — | US | disclosed |
| US-6600015-B2 | Treatment or prevention of obesity. | HOFFMANN-LA ROCHE INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1272516-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-08 | — | — | EP | disclosed |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2002-10-03 | — | — | US | disclosed |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001074844-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177036-A1 | Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity | MC4R, MC3R, MC1R | KDM1A 4616/4885MAOB 1736/4885SPHK1 2674/4885 |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | KDM1A 4445/4885MAOB 2602/4885SPHK1 2310/4885 |
| US-20050239711-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | KDM1A 4616/4885MAOB 1736/4885SPHK1 2674/4885 |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | MC4R, MC1R, MC3R | KDM1A 4753/4885MAOB 1435/4885SPHK1 4041/4885 |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | KDM1A 4568/4885MAOB 1828/4885SPHK1 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.